1 Study Coverage 1.1 Antibacterial (Drug) Resistance Product Introduction 1.2 Market by Type 1.2.1 Global Antibacterial (Drug) Resistance Market Size Growth Rate by Type 1.2.2 Telavancin (Vibativ) 1.2.3 Ceftaroline Fosamil (Teflaro/ Zinforo) 1.2.4 Fidaxomicin (Dificid / Dificlir) 1.2.5 Ceftobiprole Medocaril (Zevtera/ Zeftera/ Mabelio) 1.2.6 Dalbavancin (Dalvance/ Xydalba) 1.2.7 Tedizolid Phosphate (Sivextro) 1.2.8 Oritavancin (Orbactiv/ Nuvocid) 1.2.9 Ceftolozane-Tazobactam (Zerbaxa) 1.2.10 Ceftazidime-Avibactam (Avycaz/ Zavicefta) 1.2.11 PHASE III DRUGS 1.3 Market by Indication 1.3.1 Global Antibacterial (Drug) Resistance Market Size Growth Rate by Indication 1.3.2 Complicated Urinary Tract Infection (CUTI) 1.3.3 Complicated Intra-Abdominal Infections (CIAI) 1.3.4 Blood Stream Infections (BSI) 1.3.5 Clostridium Difficile Infections (CDI) 1.3.6 Acute Bacterial Skin And Skin Structure Infections (ABSSSI) 1.3.7 Hospital Acquired Bacterial Pneumonia/Ventilator (HABP/VABP) 1.3.8 Community Acquired Bacterial Pneumonia (CABP) 1.4 Study Objectives 1.5 Years Considered 2 Executive Summary 2.1 Global Antibacterial (Drug) Resistance Market Size, Estimates and Forecasts 2.1.1 Global Antibacterial (Drug) Resistance Revenue 2016-2027 2.1.2 Global Antibacterial (Drug) Resistance Sales 2016-2027 2.2 Global Antibacterial (Drug) Resistance, Market Size by Region: 2016 VS 2021 VS 2027 2.3 Antibacterial (Drug) Resistance Historical Market Size by Region (2016-2021) 2.3.1 Global Antibacterial (Drug) Resistance Retrospective Market Scenario in Sales by Region: 2016-2021 2.3.2 Global Antibacterial (Drug) Resistance Retrospective Market Scenario in Revenue by Region: 2016-2021 2.4 Antibacterial (Drug) Resistance Market Estimates and Projections by Region (2022-2027) 2.4.1 Global Antibacterial (Drug) Resistance Sales Forecast by Region (2022-2027) 2.4.2 Global Antibacterial (Drug) Resistance Revenue Forecast by Region (2022-2027) 3 Global Antibacterial (Drug) Resistance Competitor Landscape by Players 3.1 Global Top Antibacterial (Drug) Resistance Manufacturers by Sales 3.1.1 Global Antibacterial (Drug) Resistance Sales by Manufacturer (2016-2021) 3.1.2 Global Antibacterial (Drug) Resistance Sales Market Share by Manufacturer (2016-2021) 3.2 Global Top Antibacterial (Drug) Resistance Manufacturers by Revenue 3.2.1 Key Antibacterial (Drug) Resistance Manufacturers Covered: Ranking by Revenue 3.2.2 Global Antibacterial (Drug) Resistance Revenue by Manufacturers (2016-2021) 3.2.3 Global Antibacterial (Drug) Resistance Revenue Share by Manufacturers (2016-2021) 3.2.4 Global Antibacterial (Drug) Resistance Market Concentration Ratio (CR5 and HHI) (2016-2021) 3.2.5 Global Top 10 and Top 5 Companies by Antibacterial (Drug) Resistance Revenue in 2020 3.2.6 Global Antibacterial (Drug) Resistance Market Share by Company Type (Tier 1, Tier 2 and Tier 3) 3.3 Global Antibacterial (Drug) Resistance Price by Manufacturers 3.4 Global Antibacterial (Drug) Resistance Manufacturing Base Distribution, Product Types 3.4.1 Antibacterial (Drug) Resistance Manufacturers Manufacturing Base Distribution, Headquarters 3.4.2 Manufacturers Antibacterial (Drug) Resistance Product Type 3.4.3 Date of International Manufacturers Enter into Antibacterial (Drug) Resistance Market 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans 4 Breakdown Data by Type (2016-2027) 4.1 Global Antibacterial (Drug) Resistance Market Size by Type (2016-2021) 4.1.1 Global Antibacterial (Drug) Resistance Sales by Type (2016-2021) 4.1.2 Global Antibacterial (Drug) Resistance Revenue by Type (2016-2021) 4.1.3 Antibacterial (Drug) Resistance Average Selling Price (ASP) by Type (2016-2021) 4.2 Global Antibacterial (Drug) Resistance Market Size Forecast by Type (2022-2027) 4.2.1 Global Antibacterial (Drug) Resistance Sales Forecast by Type (2022-2027) 4.2.2 Global Antibacterial (Drug) Resistance Revenue Forecast by Type (2022-2027) 4.2.3 Antibacterial (Drug) Resistance Average Selling Price (ASP) Forecast by Type (2022-2027) 5 Breakdown Data by Indication (2016-2027) 5.1 Global Antibacterial (Drug) Resistance Market Size by Indication (2016-2021) 5.1.1 Global Antibacterial (Drug) Resistance Sales by Indication (2016-2021) 5.1.2 Global Antibacterial (Drug) Resistance Revenue by Indication (2016-2021) 5.1.3 Antibacterial (Drug) Resistance Price by Indication (2016-2021) 5.2 Antibacterial (Drug) Resistance Market Size Forecast by Indication (2022-2027) 5.2.1 Global Antibacterial (Drug) Resistance Sales Forecast by Indication (2022-2027) 5.2.2 Global Antibacterial (Drug) Resistance Revenue Forecast by Indication (2022-2027) 5.2.3 Global Antibacterial (Drug) Resistance Price Forecast by Indication (2022-2027) 6 United States by Players, Type and Indication 6.1 United States Antibacterial (Drug) Resistance Market Size YoY Growth 2016-2027 6.1.1 United States Antibacterial (Drug) Resistance Sales YoY Growth 2016-2027 6.1.2 United States Antibacterial (Drug) Resistance Revenue YoY Growth 2016-2027 6.1.3 United States Antibacterial (Drug) Resistance Market Share in Global Market 2016-2027 6.2 United States Antibacterial (Drug) Resistance Market Size by Players (International and Local Players) 6.2.1 United States Top Antibacterial (Drug) Resistance Players by Sales (2016-2021) 6.2.2 United States Top Antibacterial (Drug) Resistance Players by Revenue (2016-2021) 6.3 United States Antibacterial (Drug) Resistance Historic Market Review by Type (2016-2021) 6.3.1 United States Antibacterial (Drug) Resistance Sales Market Share by Type (2016-2021) 6.3.2 United States Antibacterial (Drug) Resistance Revenue Market Share by Type (2016-2021) 6.3.3 United States Antibacterial (Drug) Resistance Price by Type (2016-2021) 6.4 United States Antibacterial (Drug) Resistance Market Estimates and Forecasts by Type (2022-2027) 6.4.1 United States Antibacterial (Drug) Resistance Sales Forecast by Type (2022-2027) 6.4.2 United States Antibacterial (Drug) Resistance Revenue Forecast by Type (2022-2027) 6.4.3 United States Antibacterial (Drug) Resistance Price Forecast by Type (2022-2027) 6.5 United States Antibacterial (Drug) Resistance Historic Market Review by Indication (2016-2021) 6.5.1 United States Antibacterial (Drug) Resistance Sales Market Share by Indication (2016-2021) 6.5.2 United States Antibacterial (Drug) Resistance Revenue Market Share by Indication (2016-2021) 6.5.3 United States Antibacterial (Drug) Resistance Price by Indication (2016-2021) 6.6 United States Antibacterial (Drug) Resistance Market Estimates and Forecasts by Indication (2022-2027) 6.6.1 United States Antibacterial (Drug) Resistance Sales Forecast by Indication (2022-2027) 6.6.2 United States Antibacterial (Drug) Resistance Revenue Forecast by Indication (2022-2027) 6.6.3 United States Antibacterial (Drug) Resistance Price Forecast by Indication (2022-2027) 7 North America 7.1 North America Antibacterial (Drug) Resistance Market Size YoY Growth 2016-2027 7.2 North America Antibacterial (Drug) Resistance Market Facts & Figures by Country 7.2.1 North America Antibacterial (Drug) Resistance Sales by Country (2016-2021) 7.2.2 North America Antibacterial (Drug) Resistance Revenue by Country (2016-2021) 7.2.3 U.S. 7.2.4 Canada 8 Asia Pacific 8.1 Asia Pacific Antibacterial (Drug) Resistance Market Size YoY Growth 2016-2027 8.2 Asia Pacific Antibacterial (Drug) Resistance Market Facts & Figures by Region 8.2.1 Asia Pacific Antibacterial (Drug) Resistance Sales by Region (2016-2021) 8.2.2 Asia Pacific Antibacterial (Drug) Resistance Revenue by Region (2016-2021) 8.2.3 China 8.2.4 Japan 8.2.5 South Korea 8.2.6 India 8.2.7 Australia 8.2.8 Australia 8.2.9 Indonesia 8.2.10 Thailand 8.2.11 Malaysia 8.2.12 Philippines 8.2.13 Vietnam 9 Europe 9.1 Europe Antibacterial (Drug) Resistance Market Size YoY Growth 2016-2027 9.2 Europe Antibacterial (Drug) Resistance Market Facts & Figures by Country 9.2.1 Europe Antibacterial (Drug) Resistance Sales by Country (2016-2021) 9.2.2 Europe Antibacterial (Drug) Resistance Revenue by Country (2016-2021) 9.2.3 Germany 9.2.4 France 9.2.5 U.K. 9.2.6 Italy 10 Latin America 10.1 Latin America Antibacterial (Drug) Resistance Market Size YoY Growth 2016-2027 10.2 Latin America Antibacterial (Drug) Resistance Market Facts & Figures by Country 10.2.1 Latin America Antibacterial (Drug) Resistance Sales by Country (2016-2021) 10.2.2 Latin America Antibacterial (Drug) Resistance Revenue by Country (2016-2021) 10.2.3 Mexico 10.2.4 Brazil 10.2.5 Argentina 11 Middle East and Africa 11.1 Middle East and Africa Antibacterial (Drug) Resistance Market Size YoY Growth 2016-2027 11.2 Middle East and Africa Antibacterial (Drug) Resistance Market Facts & Figures by Country 11.2.1 Middle East and Africa Antibacterial (Drug) Resistance Sales by Country (2016-2021) 11.2.2 Middle East and Africa Antibacterial (Drug) Resistance Revenue by Country (2016-2021) 11.2.3 Turkey 11.2.4 Saudi Arabia 11.2.5 U.A.E 12 Company Profiles 12.1 Melinta Therapeutics 12.1.1 Melinta Therapeutics Corporation Information 12.1.2 Melinta Therapeutics Description and Business Overview 12.1.3 Melinta Therapeutics Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2016-2021) 12.1.4 Melinta Therapeutics Antibacterial (Drug) Resistance Products Offered 12.1.5 Melinta Therapeutics Recent Development 12.2 Allergan 12.2.1 Allergan Corporation Information 12.2.2 Allergan Description and Business Overview 12.2.3 Allergan Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2016-2021) 12.2.4 Allergan Antibacterial (Drug) Resistance Products Offered 12.2.5 Allergan Recent Development 12.3 Merck 12.3.1 Merck Corporation Information 12.3.2 Merck Description and Business Overview 12.3.3 Merck Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2016-2021) 12.3.4 Merck Antibacterial (Drug) Resistance Products Offered 12.3.5 Merck Recent Development 12.4 Abbott Laboratories 12.4.1 Abbott Laboratories Corporation Information 12.4.2 Abbott Laboratories Description and Business Overview 12.4.3 Abbott Laboratories Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2016-2021) 12.4.4 Abbott Laboratories Antibacterial (Drug) Resistance Products Offered 12.4.5 Abbott Laboratories Recent Development 12.5 Pfizer 12.5.1 Pfizer Corporation Information 12.5.2 Pfizer Description and Business Overview 12.5.3 Pfizer Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2016-2021) 12.5.4 Pfizer Antibacterial (Drug) Resistance Products Offered 12.5.5 Pfizer Recent Development 12.6 GSK 12.6.1 GSK Corporation Information 12.6.2 GSK Description and Business Overview 12.6.3 GSK Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2016-2021) 12.6.4 GSK Antibacterial (Drug) Resistance Products Offered 12.6.5 GSK Recent Development 12.7 PENDOPHARM 12.7.1 PENDOPHARM Corporation Information 12.7.2 PENDOPHARM Description and Business Overview 12.7.3 PENDOPHARM Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2016-2021) 12.7.4 PENDOPHARM Antibacterial (Drug) Resistance Products Offered 12.7.5 PENDOPHARM Recent Development 12.8 Absynth Biologics 12.8.1 Absynth Biologics Corporation Information 12.8.2 Absynth Biologics Description and Business Overview 12.8.3 Absynth Biologics Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2016-2021) 12.8.4 Absynth Biologics Antibacterial (Drug) Resistance Products Offered 12.8.5 Absynth Biologics Recent Development 12.9 Achaogen 12.9.1 Achaogen Corporation Information 12.9.2 Achaogen Description and Business Overview 12.9.3 Achaogen Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2016-2021) 12.9.4 Achaogen Antibacterial (Drug) Resistance Products Offered 12.9.5 Achaogen Recent Development 12.10 Acino Holdings 12.10.1 Acino Holdings Corporation Information 12.10.2 Acino Holdings Description and Business Overview 12.10.3 Acino Holdings Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2016-2021) 12.10.4 Acino Holdings Antibacterial (Drug) Resistance Products Offered 12.10.5 Acino Holdings Recent Development 12.11 Melinta Therapeutics 12.11.1 Melinta Therapeutics Corporation Information 12.11.2 Melinta Therapeutics Description and Business Overview 12.11.3 Melinta Therapeutics Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2016-2021) 12.11.4 Melinta Therapeutics Antibacterial (Drug) Resistance Products Offered 12.11.5 Melinta Therapeutics Recent Development 12.12 Austell Laboratories 12.12.1 Austell Laboratories Corporation Information 12.12.2 Austell Laboratories Description and Business Overview 12.12.3 Austell Laboratories Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2016-2021) 12.12.4 Austell Laboratories Products Offered 12.12.5 Austell Laboratories Recent Development 12.13 Assembly Biosciences 12.13.1 Assembly Biosciences Corporation Information 12.13.2 Assembly Biosciences Description and Business Overview 12.13.3 Assembly Biosciences Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2016-2021) 12.13.4 Assembly Biosciences Products Offered 12.13.5 Assembly Biosciences Recent Development 12.14 Arpida 12.14.1 Arpida Corporation Information 12.14.2 Arpida Description and Business Overview 12.14.3 Arpida Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2016-2021) 12.14.4 Arpida Products Offered 12.14.5 Arpida Recent Development 12.15 Demuris 12.15.1 Demuris Corporation Information 12.15.2 Demuris Description and Business Overview 12.15.3 Demuris Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2016-2021) 12.15.4 Demuris Products Offered 12.15.5 Demuris Recent Development 12.16 Evolva Holding 12.16.1 Evolva Holding Corporation Information 12.16.2 Evolva Holding Description and Business Overview 12.16.3 Evolva Holding Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2016-2021) 12.16.4 Evolva Holding Products Offered 12.16.5 Evolva Holding Recent Development 12.17 ContraFect 12.17.1 ContraFect Corporation Information 12.17.2 ContraFect Description and Business Overview 12.17.3 ContraFect Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2016-2021) 12.17.4 ContraFect Products Offered 12.17.5 ContraFect Recent Development 12.18 Cerexa 12.18.1 Cerexa Corporation Information 12.18.2 Cerexa Description and Business Overview 12.18.3 Cerexa Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2016-2021) 12.18.4 Cerexa Products Offered 12.18.5 Cerexa Recent Development 12.19 InterMune 12.19.1 InterMune Corporation Information 12.19.2 InterMune Description and Business Overview 12.19.3 InterMune Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2016-2021) 12.19.4 InterMune Products Offered 12.19.5 InterMune Recent Development 12.20 Isis Pharmaceuticals 12.20.1 Isis Pharmaceuticals Corporation Information 12.20.2 Isis Pharmaceuticals Description and Business Overview 12.20.3 Isis Pharmaceuticals Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2016-2021) 12.20.4 Isis Pharmaceuticals Products Offered 12.20.5 Isis Pharmaceuticals Recent Development 12.21 Lyndra 12.21.1 Lyndra Corporation Information 12.21.2 Lyndra Description and Business Overview 12.21.3 Lyndra Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2016-2021) 12.21.4 Lyndra Products Offered 12.21.5 Lyndra Recent Development 12.22 Microbecide 12.22.1 Microbecide Corporation Information 12.22.2 Microbecide Description and Business Overview 12.22.3 Microbecide Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2016-2021) 12.22.4 Microbecide Products Offered 12.22.5 Microbecide Recent Development 12.23 Morphochem 12.23.1 Morphochem Corporation Information 12.23.2 Morphochem Description and Business Overview 12.23.3 Morphochem Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2016-2021) 12.23.4 Morphochem Products Offered 12.23.5 Morphochem Recent Development 12.24 Nabriva Therapeutics 12.24.1 Nabriva Therapeutics Corporation Information 12.24.2 Nabriva Therapeutics Description and Business Overview 12.24.3 Nabriva Therapeutics Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2016-2021) 12.24.4 Nabriva Therapeutics Products Offered 12.24.5 Nabriva Therapeutics Recent Development 12.25 NanoSafe Coatings 12.25.1 NanoSafe Coatings Corporation Information 12.25.2 NanoSafe Coatings Description and Business Overview 12.25.3 NanoSafe Coatings Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2016-2021) 12.25.4 NanoSafe Coatings Products Offered 12.25.5 NanoSafe Coatings Recent Development 12.26 Novexel 12.26.1 Novexel Corporation Information 12.26.2 Novexel Description and Business Overview 12.26.3 Novexel Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2016-2021) 12.26.4 Novexel Products Offered 12.26.5 Novexel Recent Development 12.27 Osel 12.27.1 Osel Corporation Information 12.27.2 Osel Description and Business Overview 12.27.3 Osel Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2016-2021) 12.27.4 Osel Products Offered 12.27.5 Osel Recent Development 12.28 VenatoRx Pharmaceuticals 12.28.1 VenatoRx Pharmaceuticals Corporation Information 12.28.2 VenatoRx Pharmaceuticals Description and Business Overview 12.28.3 VenatoRx Pharmaceuticals Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2016-2021) 12.28.4 VenatoRx Pharmaceuticals Products Offered 12.28.5 VenatoRx Pharmaceuticals Recent Development 12.29 AAIPharma Services 12.29.1 AAIPharma Services Corporation Information 12.29.2 AAIPharma Services Description and Business Overview 12.29.3 AAIPharma Services Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2016-2021) 12.29.4 AAIPharma Services Products Offered 12.29.5 AAIPharma Services Recent Development 12.30 ANTABIO 12.30.1 ANTABIO Corporation Information 12.30.2 ANTABIO Description and Business Overview 12.30.3 ANTABIO Antibacterial (Drug) Resistance Sales, Revenue and Gross Margin (2016-2021) 12.30.4 ANTABIO Products Offered 12.30.5 ANTABIO Recent Development 13 Market Opportunities, Challenges, Risks and Influences Factors Analysis 13.1 Antibacterial (Drug) Resistance Industry Trends 13.2 Antibacterial (Drug) Resistance Market Drivers 13.3 Antibacterial (Drug) Resistance Market Challenges 13.4 Antibacterial (Drug) Resistance Market Restraints 14 Value Chain and Sales Channels Analysis 14.1 Value Chain Analysis 14.2 Antibacterial (Drug) Resistance Customers 14.3 Sales Channels Analysis 14.3.1 Sales Channels 14.3.2 Distributors 15 Research Findings and Conclusion 16 Appendix 16.1 Research Methodology 16.1.1 Methodology/Research Approach 16.1.2 Data Source 16.2 Author Details 16.3 Disclaimer

List of Tables Table 1. Global Antibacterial (Drug) Resistance Market Size Growth Rate by Type, 2016 VS 2021 VS 2027 (US$ Million) Table 2. Major Manufacturers of Telavancin (Vibativ) Table 3. Major Manufacturers of Ceftaroline Fosamil (Teflaro/ Zinforo) Table 4. Major Manufacturers of Fidaxomicin (Dificid / Dificlir) Table 5. Major Manufacturers of Ceftobiprole Medocaril (Zevtera/ Zeftera/ Mabelio) Table 6. Major Manufacturers of Dalbavancin (Dalvance/ Xydalba) Table 7. Major Manufacturers of Tedizolid Phosphate (Sivextro) Table 8. Major Manufacturers of Oritavancin (Orbactiv/ Nuvocid) Table 9. Major Manufacturers of Ceftolozane-Tazobactam (Zerbaxa) Table 10. Major Manufacturers of Ceftazidime-Avibactam (Avycaz/ Zavicefta) Table 11. Major Manufacturers of PHASE III DRUGS Table 12. Global Antibacterial (Drug) Resistance Market Size Growth Rate by Indication (2021-2027) & (K Units) Table 13. Global Antibacterial (Drug) Resistance Market Size by Region (K Units) & (US$ Million), 2016 VS 2021 VS 2027 Table 14. Global Antibacterial (Drug) Resistance Sales by Regions (2016-2021) & (K Units) Table 15. Global Antibacterial (Drug) Resistance Sales Market Share by Regions (2016-2021) Table 16. Global Antibacterial (Drug) Resistance Revenue by Regions (2016-2021) & (US$ Million) Table 17. Global Antibacterial (Drug) Resistance Sales Forecast by Region (2022-2027) & (K Units) Table 18. Global Antibacterial (Drug) Resistance Sales Market Share Forecast by Region (2022-2027) Table 19. Global Antibacterial (Drug) Resistance Revenue Forecast by Region (2022-2027) & (US$ Million) Table 20. Global Antibacterial (Drug) Resistance Revenue Market Share Forecast by Region (2022-2027) Table 21. Global Antibacterial (Drug) Resistance Sales by Manufacturers (2016-2021) (K Units) Table 22. Global Antibacterial (Drug) Resistance Sales Share by Manufacturers (2016-2021) Table 23. Ranking of Global Top Antibacterial (Drug) Resistance Manufacturers by Revenue (US$ Million) in 2020 Table 24. Antibacterial (Drug) Resistance Revenue by Manufacturers (2016-2021) (US$ Million) Table 25. Antibacterial (Drug) Resistance Revenue Share by Manufacturers (2016-2021) Table 26. Global Antibacterial (Drug) Resistance Manufacturers Market Concentration Ratio (CR5 and HHI) & (2016-2021) Table 27. Global Antibacterial (Drug) Resistance by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Antibacterial (Drug) Resistance as of 2020) Table 28. Key Manufacturers Antibacterial (Drug) Resistance Price (2016-2021) (USD/Unit) Table 29. Antibacterial (Drug) Resistance Manufacturers Manufacturing Base Distribution and Headquarters Table 30. Manufacturers Antibacterial (Drug) Resistance Product Type Table 31. Date of International Manufacturers Enter into Antibacterial (Drug) Resistance Market Table 32. Manufacturers Mergers & Acquisitions, Expansion Plans Table 33. Global Antibacterial (Drug) Resistance Sales by Type (2016-2021) (K Units) Table 34. Global Antibacterial (Drug) Resistance Sales Share by Type (2016-2021) Table 35. Global Antibacterial (Drug) Resistance Revenue by Type (2016-2021) (US$ Million) Table 36. Global Antibacterial (Drug) Resistance Revenue Share by Type (2016-2021) Table 37. Antibacterial (Drug) Resistance Average Selling Price (ASP) by Type (2016-2021) & (USD/Unit) Table 38. Global Antibacterial (Drug) Resistance Sales Forecast by Type (2022-2027) & (K Units) Table 39. Global Antibacterial (Drug) Resistance Sales Market Share Forecast by Type (2022-2027) Table 40. Global Antibacterial (Drug) Resistance Revenue Forecast V (2022-2027) & (US$ Million) Table 41. Global Antibacterial (Drug) Resistance Revenue Market Share Forecast by Type (2022-2027) Table 42. Global Antibacterial (Drug) Resistance Average Selling Price (ASP) Forecast by Type (2022-2027) & (USD/Unit) Table 43. Global Antibacterial (Drug) Resistance Sales by Indication (2016-2021) (K Units) Table 44. Global Antibacterial (Drug) Resistance Sales Share by Indication (2016-2021) Table 45. Global Antibacterial (Drug) Resistance Revenue by Indication (2016-2021) (US$ Million) Table 46. Global Antibacterial (Drug) Resistance Revenue Share by Indication (2016-2021) Table 47. Antibacterial (Drug) Resistance Average Selling Price (ASP) by Indication (2016-2021) & (USD/Unit) Table 48. Global Antibacterial (Drug) Resistance Sales Forecast by Indication (2022-2027) & (K Units) Table 49. Global Antibacterial (Drug) Resistance Sales Market Share Forecast by Indication (2022-2027) Table 50. Global Antibacterial (Drug) Resistance Revenue Forecast by Indication (2022-2027) & (US$ Million) Table 51. Global Antibacterial (Drug) Resistance Revenue Market Share Forecast by Indication (2022-2027) Table 52. Global Antibacterial (Drug) Resistance Average Selling Price (ASP) Forecast by Indication (2022-2027) & (USD/Unit) Table 53. United States Antibacterial (Drug) Resistance Sales (K Units) of Key Companies (2016-2021) Table 54. United States Antibacterial (Drug) Resistance Sales Share by Company (2016-2021) Table 55. United States Antibacterial (Drug) Resistance Revenue (US$ Million) by Company (2016-2021) Table 56. United States Antibacterial (Drug) Resistance Revenue Share by Company (2016-2021) Table 57. United States Antibacterial (Drug) Resistance Sales (K Units) by Type (2016-2021) Table 58. United States Antibacterial (Drug) Resistance Sales Share by Type (2016-2021) Table 59. United States Antibacterial (Drug) Resistance Revenue (US$ Million) Market Share by Type (2016-2021) Table 60. United States Antibacterial (Drug) Resistance Price (USD/Unit) by Type (2016-2021) Table 61. United States Antibacterial (Drug) Resistance Sales (K Units) by Type (2022-2027) Table 62. United States Antibacterial (Drug) Resistance Sales Share by Type (2022-2027) Table 63. United States Antibacterial (Drug) Resistance Revenue (US$ Million) Market Share by Type (2022-2027) Table 64. United States Antibacterial (Drug) Resistance Revenue Share by Type (2022-2027) Table 65. United States Antibacterial (Drug) Resistance Price (USD/Unit) by Type (2022-2027) Table 66. United States Antibacterial (Drug) Resistance Sales (K Units) by Indication (2016-2021) Table 67. United States Antibacterial (Drug) Resistance Sales Share by Indication (2016-2021) Table 68. United States Antibacterial (Drug) Resistance Revenue (US$ Million) Market Share by Indication (2016-2021) Table 69. United States Antibacterial (Drug) Resistance Price (USD/Unit) by Indication (2016-2021) Table 70. United States Antibacterial (Drug) Resistance Sales (K Units) by Indication (2022-2027) Table 71. United States Antibacterial (Drug) Resistance Sales Share by Indication (2022-2027) Table 72. United States Antibacterial (Drug) Resistance Revenue (US$ Million) Market Share by Indication (2022-2027) Table 73. United States Antibacterial (Drug) Resistance Revenue Share by Indication (2022-2027) Table 74. United States Antibacterial (Drug) Resistance Price (USD/Unit) by Indication (2022-2027) Table 75. North America Antibacterial (Drug) Resistance Sales by Country (2016-2021) & (K Units) Table 76. North America Antibacterial (Drug) Resistance Sales Market Share by Country (2016-2021) Table 77. North America Antibacterial (Drug) Resistance Revenue by Country (2016-2021) & (US$ Million) Table 78. North America Antibacterial (Drug) Resistance Revenue Market Share by Country (2016-2021) Table 79. Asia Pacific Antibacterial (Drug) Resistance Sales by Region (2016-2021) & (K Units) Table 80. Asia Pacific Antibacterial (Drug) Resistance Sales Market Share by Region (2016-2021) Table 81. Asia Pacific Antibacterial (Drug) Resistance Revenue by Region (2016-2021) & (US$ Million) Table 82. Asia Pacific Antibacterial (Drug) Resistance Revenue Market Share by Region (2016-2021) Table 83. Europe Antibacterial (Drug) Resistance Sales by Country (2016-2021) & (K Units) Table 84. Europe Antibacterial (Drug) Resistance Sales Market Share by Country (2016-2021) Table 85. Europe Antibacterial (Drug) Resistance Revenue by Country (2016-2021) & (US$ Million) Table 86. Europe Antibacterial (Drug) Resistance Revenue Market Share by Country (2016-2021) Table 87. Latin America Antibacterial (Drug) Resistance Sales by Country (2016-2021) & (K Units) Table 88. Latin America Antibacterial (Drug) Resistance Sales Market Share by Country (2016-2021) Table 89. Latin Americaa Antibacterial (Drug) Resistance Revenue by Country (2016-2021) & (US$ Million) Table 90. Latin America Antibacterial (Drug) Resistance Revenue Market Share by Country (2016-2021) Table 91. Middle East and Africa Antibacterial (Drug) Resistance Sales by Country (2016-2021) & (K Units) Table 92. Middle East and Africa Antibacterial (Drug) Resistance Sales Market Share by Country (2016-2021) Table 93. Middle East and Africa Antibacterial (Drug) Resistance Revenue by Country (2016-2021) & (US$ Million) Table 94. Middle East and Africa Antibacterial (Drug) Resistance Revenue Market Share by Country (2016-2021) Table 95. Melinta Therapeutics Corporation Information Table 96. Melinta Therapeutics Description and Business Overview Table 97. Melinta Therapeutics Antibacterial (Drug) Resistance Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2016-2021) Table 98. Melinta Therapeutics Antibacterial (Drug) Resistance Product Table 99. Melinta Therapeutics Recent Development Table 100. Allergan Corporation Information Table 101. Allergan Description and Business Overview Table 102. Allergan Antibacterial (Drug) Resistance Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2016-2021) Table 103. Allergan Product Table 104. Allergan Recent Development Table 105. Merck Corporation Information Table 106. Merck Description and Business Overview Table 107. Merck Antibacterial (Drug) Resistance Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2016-2021) Table 108. Merck Product Table 109. Merck Recent Development Table 110. Abbott Laboratories Corporation Information Table 111. Abbott Laboratories Description and Business Overview Table 112. Abbott Laboratories Antibacterial (Drug) Resistance Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2016-2021) Table 113. Abbott Laboratories Product Table 114. Abbott Laboratories Recent Development Table 115. Pfizer Corporation Information Table 116. Pfizer Description and Business Overview Table 117. Pfizer Antibacterial (Drug) Resistance Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2016-2021) Table 118. Pfizer Product Table 119. Pfizer Recent Development Table 120. GSK Corporation Information Table 121. GSK Description and Business Overview Table 122. GSK Antibacterial (Drug) Resistance Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2016-2021) Table 123. GSK Product Table 124. GSK Recent Development Table 125. PENDOPHARM Corporation Information Table 126. PENDOPHARM Description and Business Overview Table 127. PENDOPHARM Antibacterial (Drug) Resistance Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2016-2021) Table 128. PENDOPHARM Product Table 129. PENDOPHARM Recent Development Table 130. Absynth Biologics Corporation Information Table 131. Absynth Biologics Description and Business Overview Table 132. Absynth Biologics Antibacterial (Drug) Resistance Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2016-2021) Table 133. Absynth Biologics Product Table 134. Absynth Biologics Recent Development Table 135. Achaogen Corporation Information Table 136. Achaogen Description and Business Overview Table 137. Achaogen Antibacterial (Drug) Resistance Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2016-2021) Table 138. Achaogen Product Table 139. Achaogen Recent Development Table 140. Acino Holdings Corporation Information Table 141. Acino Holdings Description and Business Overview Table 142. Acino Holdings Antibacterial (Drug) Resistance Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2016-2021) Table 143. Acino Holdings Product Table 144. Acino Holdings Recent Development Table 145. Aventis Pharma Corporation Information Table 146. Aventis Pharma Description and Business Overview Table 147. Aventis Pharma Antibacterial (Drug) Resistance Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2016-2021) Table 148. Aventis Pharma Product Table 149. Aventis Pharma Recent Development Table 150. Austell Laboratories Corporation Information Table 151. Austell Laboratories Description and Business Overview Table 152. Austell Laboratories Antibacterial (Drug) Resistance Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2016-2021) Table 153. Austell Laboratories Product Table 154. Austell Laboratories Recent Development Table 155. Assembly Biosciences Corporation Information Table 156. Assembly Biosciences Description and Business Overview Table 157. Assembly Biosciences Antibacterial (Drug) Resistance Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2016-2021) Table 158. Assembly Biosciences Product Table 159. Assembly Biosciences Recent Development Table 160. Arpida Corporation Information Table 161. Arpida Description and Business Overview Table 162. Arpida Antibacterial (Drug) Resistance Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2016-2021) Table 163. Arpida Product Table 164. Arpida Recent Development Table 165. Demuris Corporation Information Table 166. Demuris Description and Business Overview Table 167. Demuris Antibacterial (Drug) Resistance Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2016-2021) Table 168. Demuris Product Table 169. Demuris Recent Development Table 170. Evolva Holding Corporation Information Table 171. Evolva Holding Description and Business Overview Table 172. Evolva Holding Antibacterial (Drug) Resistance Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2016-2021) Table 173. Evolva Holding Product Table 174. Evolva Holding Recent Development Table 175. ContraFect Corporation Information Table 176. ContraFect Description and Business Overview Table 177. ContraFect Antibacterial (Drug) Resistance Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2016-2021) Table 178. ContraFect Product Table 179. ContraFect Recent Development Table 180. Cerexa Corporation Information Table 181. Cerexa Description and Business Overview Table 182. Cerexa Antibacterial (Drug) Resistance Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2016-2021) Table 183. Cerexa Product Table 184. Cerexa Recent Development Table 185. InterMune Corporation Information Table 186. InterMune Description and Business Overview Table 187. InterMune Antibacterial (Drug) Resistance Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2016-2021) Table 188. InterMune Product Table 189. InterMune Recent Development Table 190. Isis Pharmaceuticals Corporation Information Table 191. Isis Pharmaceuticals Description and Business Overview Table 192. Isis Pharmaceuticals Antibacterial (Drug) Resistance Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2016-2021) Table 193. Isis Pharmaceuticals Product Table 194. Isis Pharmaceuticals Recent Development Table 195. Lyndra Corporation Information Table 196. Lyndra Description and Business Overview Table 197. Lyndra Antibacterial (Drug) Resistance Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2016-2021) Table 198. Lyndra Product Table 199. Lyndra Recent Development Table 200. Microbecide Corporation Information Table 201. Microbecide Description and Business Overview Table 202. Microbecide Antibacterial (Drug) Resistance Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2016-2021) Table 203. Microbecide Product Table 204. Microbecide Recent Development Table 205. Morphochem Corporation Information Table 206. Morphochem Description and Business Overview Table 207. Morphochem Antibacterial (Drug) Resistance Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2016-2021) Table 208. Morphochem Product Table 209. Morphochem Recent Development Table 210. Nabriva Therapeutics Corporation Information Table 211. Nabriva Therapeutics Description and Business Overview Table 212. Nabriva Therapeutics Antibacterial (Drug) Resistance Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2016-2021) Table 213. Nabriva Therapeutics Product Table 214. Nabriva Therapeutics Recent Development Table 215. NanoSafe Coatings Corporation Information Table 216. NanoSafe Coatings Description and Business Overview Table 217. NanoSafe Coatings Antibacterial (Drug) Resistance Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2016-2021) Table 218. NanoSafe Coatings Product Table 219. NanoSafe Coatings Recent Development Table 220. Novexel Corporation Information Table 221. Novexel Description and Business Overview Table 222. Novexel Antibacterial (Drug) Resistance Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2016-2021) Table 223. Novexel Product Table 224. Novexel Recent Development Table 225. Osel Corporation Information Table 226. Osel Description and Business Overview Table 227. Osel Antibacterial (Drug) Resistance Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2016-2021) Table 228. Osel Product Table 229. Osel Recent Development Table 230. VenatoRx Pharmaceuticals Corporation Information Table 231. VenatoRx Pharmaceuticals Description and Business Overview Table 232. VenatoRx Pharmaceuticals Antibacterial (Drug) Resistance Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2016-2021) Table 233. VenatoRx Pharmaceuticals Product Table 234. VenatoRx Pharmaceuticals Recent Development Table 235. AAIPharma Services Corporation Information Table 236. AAIPharma Services Description and Business Overview Table 237. AAIPharma Services Antibacterial (Drug) Resistance Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2016-2021) Table 238. AAIPharma Services Product Table 239. AAIPharma Services Recent Development Table 240. ANTABIO Corporation Information Table 241. ANTABIO Description and Business Overview Table 242. ANTABIO Antibacterial (Drug) Resistance Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2016-2021) Table 243. ANTABIO Product Table 244. ANTABIO Recent Development Table 245. Antibacterial (Drug) Resistance Market Trends Table 246. Antibacterial (Drug) Resistance Market Drivers Table 247. Antibacterial (Drug) Resistance Market Challenges Table 248. Antibacterial (Drug) Resistance Market Restraints Table 249. Antibacterial (Drug) Resistance Customers List Table 250. Antibacterial (Drug) Resistance Distributors List Table 251. Research Programs/Design for This Report Table 252. Key Data Information from Secondary Sources Table 253. Key Data Information from Primary Sources List of Figures Figure 1. Antibacterial (Drug) Resistance Product Picture Figure 2. Global Antibacterial (Drug) Resistance Sales Market Share by Type in 2020 & 2027 Figure 3. Telavancin (Vibativ) Product Picture Figure 4. Ceftaroline Fosamil (Teflaro/ Zinforo) Product Picture Figure 5. Fidaxomicin (Dificid / Dificlir) Product Picture Figure 6. Ceftobiprole Medocaril (Zevtera/ Zeftera/ Mabelio) Product Picture Figure 7. Dalbavancin (Dalvance/ Xydalba) Product Picture Figure 8. Tedizolid Phosphate (Sivextro) Product Picture Figure 9. Oritavancin (Orbactiv/ Nuvocid) Product Picture Figure 10. Ceftolozane-Tazobactam (Zerbaxa) Product Picture Figure 11. Ceftazidime-Avibactam (Avycaz/ Zavicefta) Product Picture Figure 12. PHASE III DRUGS Product Picture Figure 13. Global Antibacterial (Drug) Resistance Sales Market Share by Indication in 2020 & 2027 Figure 14. Complicated Urinary Tract Infection (CUTI) Figure 15. Complicated Intra-Abdominal Infections (CIAI) Figure 16. Blood Stream Infections (BSI) Figure 17. Clostridium Difficile Infections (CDI) Figure 18. Acute Bacterial Skin And Skin Structure Infections (ABSSSI) Figure 19. Hospital Acquired Bacterial Pneumonia/Ventilator (HABP/VABP) Figure 20. Community Acquired Bacterial Pneumonia (CABP) Figure 21. Antibacterial (Drug) Resistance Report Years Considered Figure 22. Global Antibacterial (Drug) Resistance Market Size, (US$ Million), 2016 VS 2021 VS 2027 Figure 23. Global Antibacterial (Drug) Resistance Market Size 2016-2027 (US$ Million) Figure 24. Global Antibacterial (Drug) Resistance Sales 2016-2027 (K Units) Figure 25. Global Antibacterial (Drug) Resistance Market Size Market Share by Region: 2021 Versus 2027 Figure 26. Global Antibacterial (Drug) Resistance Sales Market Share by Region (2016-2021) Figure 27. Global Antibacterial (Drug) Resistance Sales Market Share by Region in 2020 Figure 28. Global Antibacterial (Drug) Resistance Revenue Market Share by Region (2016-2021) Figure 29. Global Antibacterial (Drug) Resistance Revenue Market Share by Region in 2020 Figure 30. Global Antibacterial (Drug) Resistance Sales Share by Manufacturer in 2020 Figure 31. The Top 10 and 5 Players Market Share by Antibacterial (Drug) Resistance Revenue in 2020 Figure 32. Antibacterial (Drug) Resistance Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2016 VS 2020 Figure 33. Global Antibacterial (Drug) Resistance Sales Market Share by Type (2016-2021) Figure 34. Global Antibacterial (Drug) Resistance Sales Market Share by Type in 2020 Figure 35. Global Antibacterial (Drug) Resistance Revenue Market Share by Type (2016-2021) Figure 36. Global Antibacterial (Drug) Resistance Revenue Market Share by Type in 2020 Figure 37. Global Antibacterial (Drug) Resistance Sales Market Share by Indication (2016-2021) Figure 38. Global Antibacterial (Drug) Resistance Sales Market Share by Indication in 2020 Figure 39. Global Antibacterial (Drug) Resistance Revenue Market Share by Indication (2016-2021) Figure 40. Global Antibacterial (Drug) Resistance Revenue Market Share by Indication in 2020 Figure 41. United States Antibacterial (Drug) Resistance Sales Growth Rate 2016-2027 (K Units) Figure 42. United States Antibacterial (Drug) Resistance Revenue Growth Rate 2016-2027 (US$ Million) Figure 43. United States Antibacterial (Drug) Resistance Market Share in Global Market 2016-2027 Figure 44. United States 5 and 10 Largest Antibacterial (Drug) Resistance Players Market Share by Revenue in Antibacterial (Drug) Resistance in 2020 Figure 45. United States Antibacterial (Drug) Resistance Revenue Share by Type (2016-2021) Figure 46. United States Antibacterial (Drug) Resistance Revenue Growth Rate by Type in 2016 & 2020 Figure 47. United States Antibacterial (Drug) Resistance Revenue Share by Indication (2016-2021) Figure 48. United States Antibacterial (Drug) Resistance Revenue Growth Rate by Indication in 2016 & 2020 Figure 49. North America Antibacterial (Drug) Resistance Sales Growth Rate 2016-2021 (K Units) Figure 50. North America Antibacterial (Drug) Resistance Revenue Growth Rate 2016-2021 (US$ Million) Figure 51. North America Antibacterial (Drug) Resistance Sales Market Share by Country in 2020 Figure 52. North America Antibacterial (Drug) Resistance Revenue Market Share by Country in 2020 Figure 53. U.S. Antibacterial (Drug) Resistance Sales Growth Rate (2016-2021) (K Units) Figure 54. U.S. Antibacterial (Drug) Resistance Revenue Growth Rate (2016-2021) (US$ Million) Figure 55. Canada Antibacterial (Drug) Resistance Sales Growth Rate (2016-2021) (K Units) Figure 56. Canada Antibacterial (Drug) Resistance Revenue Growth Rate (2016-2021) (US$ Million) Figure 57. Europe Antibacterial (Drug) Resistance Sales Growth Rate 2016-2021 (K Units) Figure 58. Europe Antibacterial (Drug) Resistance Revenue Growth Rate 2016-2021 (US$ Million) Figure 59. Europe Antibacterial (Drug) Resistance Sales Market Share by Country in 2020 Figure 60. Europe Antibacterial (Drug) Resistance Revenue Market Share by Country in 2020 Figure 61. Germany Antibacterial (Drug) Resistance Sales Growth Rate (2016-2021) (K Units) Figure 62. Germany Antibacterial (Drug) Resistance Revenue Growth Rate (2016-2021) (US$ Million) Figure 63. France Antibacterial (Drug) Resistance Sales Growth Rate (2016-2021) (K Units) Figure 64. France Antibacterial (Drug) Resistance Revenue Growth Rate (2016-2021) (US$ Million) Figure 65. U.K. Antibacterial (Drug) Resistance Sales Growth Rate (2016-2021) (K Units) Figure 66. U.K. Antibacterial (Drug) Resistance Revenue Growth Rate (2016-2021) (US$ Million) Figure 67. Italy Antibacterial (Drug) Resistance Sales Growth Rate (2016-2021) (K Units) Figure 68. Italy Antibacterial (Drug) Resistance Revenue Growth Rate (2016-2021) (US$ Million) Figure 69. Russia Antibacterial (Drug) Resistance Sales Growth Rate (2016-2021) (K Units) Figure 70. Russia Antibacterial (Drug) Resistance Revenue Growth Rate (2016-2021) (US$ Million) Figure 71. Asia Pacific Antibacterial (Drug) Resistance Sales Growth Rate 2016-2021 (K Units) Figure 72. Asia Pacific Antibacterial (Drug) Resistance Revenue Growth Rate 2016-2021 (US$ Million) Figure 73. Asia Pacific Antibacterial (Drug) Resistance Sales Market Share by Region in 2020 Figure 74. Asia Pacific Antibacterial (Drug) Resistance Revenue Market Share by Region in 2020 Figure 75. China Antibacterial (Drug) Resistance Sales Growth Rate (2016-2021) (K Units) Figure 76. China Antibacterial (Drug) Resistance Revenue Growth Rate (2016-2021) (US$ Million) Figure 77. Japan Antibacterial (Drug) Resistance Sales Growth Rate (2016-2021) (K Units) Figure 78. Japan Antibacterial (Drug) Resistance Revenue Growth Rate (2016-2021) (US$ Million) Figure 79. South Korea Antibacterial (Drug) Resistance Sales Growth Rate (2016-2021) (K Units) Figure 80. South Korea Antibacterial (Drug) Resistance Revenue Growth Rate (2016-2021) (US$ Million) Figure 81. India Antibacterial (Drug) Resistance Sales Growth Rate (2016-2021) (K Units) Figure 82. India Antibacterial (Drug) Resistance Revenue Growth Rate (2016-2021) (US$ Million) Figure 83. Australia Antibacterial (Drug) Resistance Sales Growth Rate (2016-2021) (K Units) Figure 84. Australia Antibacterial (Drug) Resistance Revenue Growth Rate (2016-2021) (US$ Million) Figure 85. Taiwan Antibacterial (Drug) Resistance Sales Growth Rate (2016-2021) (K Units) Figure 86. Taiwan Antibacterial (Drug) Resistance Revenue Growth Rate (2016-2021) (US$ Million) Figure 87. Indonesia Antibacterial (Drug) Resistance Sales Growth Rate (2016-2021) (K Units) Figure 88. Indonesia Antibacterial (Drug) Resistance Revenue Growth Rate (2016-2021) (US$ Million) Figure 89. Thailand Antibacterial (Drug) Resistance Sales Growth Rate (2016-2021) (K Units) Figure 90. Thailand Antibacterial (Drug) Resistance Revenue Growth Rate (2016-2021) (US$ Million) Figure 91. Malaysia Antibacterial (Drug) Resistance Sales Growth Rate (2016-2021) (K Units) Figure 92. Malaysia Antibacterial (Drug) Resistance Revenue Growth Rate (2016-2021) (US$ Million) Figure 93. Philippines Antibacterial (Drug) Resistance Sales Growth Rate (2016-2021) (K Units) Figure 94. Philippines Antibacterial (Drug) Resistance Revenue Growth Rate (2016-2021) (US$ Million) Figure 95. Vietnam Antibacterial (Drug) Resistance Sales Growth Rate (2016-2021) (K Units) Figure 96. Vietnam Antibacterial (Drug) Resistance Revenue Growth Rate (2016-2021) (US$ Million) Figure 97. Latin America Antibacterial (Drug) Resistance Sales Growth Rate 2016-2021 (K Units) Figure 98. Latin America Antibacterial (Drug) Resistance Revenue Growth Rate 2016-2021 (US$ Million) Figure 99. Latin America Antibacterial (Drug) Resistance Sales Market Share by Country in 2020 Figure 100. Latin America Antibacterial (Drug) Resistance Revenue Market Share by Country in 2020 Figure 101. Mexico Antibacterial (Drug) Resistance Sales Growth Rate (2016-2021) (K Units) Figure 102. Mexico Antibacterial (Drug) Resistance Revenue Growth Rate (2016-2021) (US$ Million) Figure 103. Brazil Antibacterial (Drug) Resistance Sales Growth Rate (2016-2021) (K Units) Figure 104. Brazil Antibacterial (Drug) Resistance Revenue Growth Rate (2016-2021) (US$ Million) Figure 105. Argentina Antibacterial (Drug) Resistance Sales Growth Rate (2016-2021) (K Units) Figure 106. Argentina Antibacterial (Drug) Resistance Revenue Growth Rate (2016-2021) (US$ Million) Figure 107. Middle East and Africa Antibacterial (Drug) Resistance Sales Growth Rate 2016-2021 (K Units) Figure 108. Middle East and Africa Antibacterial (Drug) Resistance Revenue Growth Rate 2016-

Melinta Therapeutics Allergan Merck Abbott Laboratories Pfizer GSK PENDOPHARM Absynth Biologics Achaogen Acino Holdings Aventis Pharma Austell Laboratories Assembly Biosciences Arpida Demuris Evolva Holding ContraFect Cerexa InterMune Isis Pharmaceuticals Lyndra Microbecide Morphochem Nabriva Therapeutics NanoSafe Coatings Novexel Osel VenatoRx Pharmaceuticals AAIPharma Services ANTABIO